The KRT18 Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the KRT18 gene in the A2780 ovarian carcinoma background. This product provides a heterogeneous loss-of-function model for investigating the roles of the type I intermediate filament protein keratin 18 in epithelial cell biology. The polyclonal format offers a robust system for functional genomics studies, capturing the diversity of CRISPR/Cas9-mediated gene disruption events without clonal selection. Researchers can employ this tool to dissect KRT18-dependent mechanisms in a cancer-relevant setting, with versatile applications in signal transduction, cytoskeletal dynamics, and drug response profiling.
The A2780 host cell line is an epithelial-like ovarian carcinoma model originally established from an untreated patient with ovarian adenocarcinoma. This cell line retains key epithelial characteristics, including cytokeratin expression and adherent growth, making it an appropriate platform for studying intermediate filament function and epithelial homeostasis. A2780 cells are widely used in ovarian cancer research for evaluating oncogenic signaling, apoptosis, migration, and chemotherapeutic sensitivity. The integration of a KRT18 knockout in this well-characterized background allows for direct assessment of keratin 18 contributions to malignant phenotypes in a disease-relevant context.
KRT18 encodes a type I intermediate filament protein that obligately heterodimerizes with its type II partner KRT8 to form the intermediate filament network in simple epithelia. This network provides mechanical resilience and is dynamically regulated during processes such as mitosis, apoptosis, and epithelial-to-mesenchymal transition (EMT). KRT18 expression is transcriptionally activated by TP63, ETS1, and SP1, and is modulated by TGF-beta and EGF signaling. At the post-translational level, KRT18 interacts with TRADD and 14-3-3 sigma to sequester pro-apoptotic factors, thereby suppressing caspase-3 activation and cytochrome c release. Additionally, KRT18 cross-talks with Bcl-2 family members, positioning it at a critical node connecting cytoskeletal integrity to cell survival. Disruption of KRT18 leads to loss of filament organization, increased susceptibility to caspase-mediated apoptosis, and altered mechanosignaling.
In the A2780 ovarian carcinoma model, KRT18 knockout profoundly impacts cellular architecture and stress responses. Loss of keratin 18 compromises intermediate filament networks, reducing mechanical stability and sensitizing cells to apoptotic stimuli, including TNF and FAS engagement. This sensitization is mediated through relief of caspase-3 inhibition, as KRT18 normally restricts cytochrome c release from mitochondria. Moreover, KRT18 deficiency may alter EMT-associated traits, influencing cell migration and invasion potential. Given A2780 cells?? utility in chemoresistance studies, this knockout model is particularly valuable for examining how keratin intermediate filaments modulate responses to platinum-based and taxane chemotherapies. The polyclonal population captures a spectrum of editing efficiencies, enabling studies of gene dosage effects in a heterogeneous cell pool.
This knockout product is ideally suited for a range of downstream assays, including western blotting and immunofluorescence for validating keratin network disruption, apoptosis assays via caspase-3/7 activation and cytochrome c release, and migration/invasion assays using Boyden chambers or wound-healing setups. Researchers can also employ flow cytometry for cell cycle and apoptosis profiling, and drug sensitivity assays to correlate KRT18 status with chemoresistance. Additionally, the model supports biomarker evaluation and mechanistic studies on intermediate filament?Capoptosis crosstalk. For further technical details, please contact Ascent Research.
